BR112021014373A2 - Métodos para produzir e usar alfa 1-antitripsina (aat) recombinante e composições da mesma - Google Patents
Métodos para produzir e usar alfa 1-antitripsina (aat) recombinante e composições da mesmaInfo
- Publication number
- BR112021014373A2 BR112021014373A2 BR112021014373A BR112021014373A BR112021014373A2 BR 112021014373 A2 BR112021014373 A2 BR 112021014373A2 BR 112021014373 A BR112021014373 A BR 112021014373A BR 112021014373 A BR112021014373 A BR 112021014373A BR 112021014373 A2 BR112021014373 A2 BR 112021014373A2
- Authority
- BR
- Brazil
- Prior art keywords
- aat
- proteins
- recombinant
- methods
- antitrypsin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title abstract 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title abstract 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 8
- 108090000623 proteins and genes Proteins 0.000 abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 abstract 1
- 239000000969 carrier Substances 0.000 abstract 1
- 239000013613 expression plasmid Substances 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
métodos para produzir e usar alfa 1- antitripsina (aat) recombinante e composições da mesma. as modalidades da presente invenção geralmente se referem a proteínas alfa 1-antitripsina (aat) recombinantes, incluindo variantes de aat humana com mutações introduzidas individualmente, composições contendo tais proteínas aat recombinantes e carreadores, plasmídeos de expressão ou vetores e células hospedeiras que expressam tais proteínas aat recombinantes, métodos de produção de tais proteínas aat recombinantes e métodos de tratamento de doenças, distúrbios e condições relacionadas à deficiência de aat ou doenças, distúrbios e condições que resultam em dano ao tecido induzido por protease em um sujeito em necessidade com as proteínas aat recombinantes e/ou composições de proteína aat recombinante descritas no presente documento. as proteínas aat recombinantes derivadas de células hospedeiras de mamífero conforme produzidas pelos métodos descritos no presente documento podem ser produzidas em grandes quantidades, sem quaisquer componentes animais, isto é, altamente puras, altamente glicosiladas e podem ser vantajosamente usadas em relação a aat derivada de plasma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796159P | 2019-01-24 | 2019-01-24 | |
| PCT/IB2020/050581 WO2020152653A1 (en) | 2019-01-24 | 2020-01-24 | Methods of producing and using recombinant alpha 1-antitrypsin (aat) and compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021014373A2 true BR112021014373A2 (pt) | 2021-11-03 |
Family
ID=69467597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021014373A BR112021014373A2 (pt) | 2019-01-24 | 2020-01-24 | Métodos para produzir e usar alfa 1-antitripsina (aat) recombinante e composições da mesma |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220112270A1 (pt) |
| EP (1) | EP3914614A1 (pt) |
| CN (1) | CN114651005A (pt) |
| AU (1) | AU2020211080A1 (pt) |
| BR (1) | BR112021014373A2 (pt) |
| CA (1) | CA3127750A1 (pt) |
| IL (1) | IL285042A (pt) |
| WO (1) | WO2020152653A1 (pt) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5399684A (en) | 1982-05-20 | 1995-03-21 | Washington Research Foundation | DNA sequences expressing mammalian alpha-1-antitrypsin |
| EP0304971B1 (en) | 1982-08-13 | 1998-02-04 | ZymoGenetics, Inc. | A method of producing a polypeptide having the protease inhibition activity of mammalian alpha-1-antitrypsin |
| JPS60186290A (ja) | 1983-08-10 | 1985-09-21 | チモ−ジエネテイツクス インコ−ポレ−テツド | アルフア−１−アンチトリプシンを細菌に表現させる方法 |
| US4752576A (en) | 1984-06-14 | 1988-06-21 | Chiron Corporation | Expression of α-1 antitrypsin in yeast |
| US4839283A (en) | 1986-12-30 | 1989-06-13 | Zymogenetics, Inc. | Method of expressing alpha-1-antitrypsin in yeast |
| US5650503A (en) | 1988-11-11 | 1997-07-22 | Ppl Therapeutics (Scotland) Limited | Genetic construct of which protein coding DNA comprises introns and is designed for protein production in transgenic animals |
| US6127145A (en) | 1997-02-13 | 2000-10-03 | Applied Phytologics, Inc. | Production of α1 -antitrypsin in plants |
| US8357661B2 (en) * | 2009-04-23 | 2013-01-22 | Crucell Holland B.V. | Recombinant human Alpha1-antitrypsin |
| WO2011123830A2 (en) * | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| EP3155117A4 (en) * | 2014-06-11 | 2017-11-22 | Beth Israel Deaconess Medical Center, Inc. | Alpha1-antitrypsin compositions and methods of treating autoimmune diseases |
| WO2017109039A1 (en) * | 2015-12-22 | 2017-06-29 | Vrije Universiteit Brussel | Endothelium-specific nucleic acid regulatory elements and methods and use thereof |
-
2020
- 2020-01-24 BR BR112021014373A patent/BR112021014373A2/pt unknown
- 2020-01-24 AU AU2020211080A patent/AU2020211080A1/en active Pending
- 2020-01-24 CA CA3127750A patent/CA3127750A1/en active Pending
- 2020-01-24 WO PCT/IB2020/050581 patent/WO2020152653A1/en unknown
- 2020-01-24 EP EP20703530.4A patent/EP3914614A1/en active Pending
- 2020-01-24 CN CN202080022460.8A patent/CN114651005A/zh active Pending
-
2021
- 2021-07-21 IL IL285042A patent/IL285042A/en unknown
- 2021-07-22 US US17/383,109 patent/US20220112270A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020152653A1 (en) | 2020-07-30 |
| EP3914614A1 (en) | 2021-12-01 |
| AU2020211080A1 (en) | 2021-08-05 |
| US20220112270A1 (en) | 2022-04-14 |
| IL285042A (en) | 2021-09-30 |
| CN114651005A (zh) | 2022-06-21 |
| CA3127750A1 (en) | 2020-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018005215A2 (es) | Construcciones específicas del hígado para expresión del factor viii | |
| BR112017007892A2 (pt) | composição, e, preparação injetável. | |
| BR0109494A (pt) | Produção de fatores recombinantes de coagulação do sangue em linhas celulares humanas | |
| BR112017017028A2 (pt) | rnai variante | |
| Meiners et al. | Regulation of the proteasome: evaluating the lung proteasome as a new therapeutic target | |
| BR112013021526A2 (pt) | anticorpo fc específico para fcyriib | |
| EA201170993A1 (ru) | Удлиненные рекомбинантные полипептиды и содержащие их композиции | |
| GEP20135967B (en) | Improved reconstituted surfactant composition containing surfactant protein b (sp-b), and surfactant protein c (sp-c) analogs | |
| WO2017053732A3 (en) | Composition and method for treating complement-mediated disease | |
| BR112022015979A2 (pt) | Vetores de terapia genética para tratamento de doenças cardíacas | |
| NZ708091A (en) | Stabilized insulin-like growth factor polypeptides | |
| PE20220930A1 (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica | |
| BR112021017827A2 (pt) | Proteínas de fusão, bactérias recombinantes e fragmentos de exosporium para o controle de pestes e saúde das plantas | |
| BR112022008214A2 (pt) | Composições e métodos para tratar perda auditiva neurossensorial usando sistemas de vetor duplo de otoferlina | |
| BR112021014373A2 (pt) | Métodos para produzir e usar alfa 1-antitripsina (aat) recombinante e composições da mesma | |
| MX2022007546A (es) | Interferon-alfa-2 modificado que tiene inmunogenicidad reducida. | |
| Lin et al. | Calpain inhibitors ameliorate muscle wasting in a cachectic mouse model bearing CT26 colorectal adenocarcinoma | |
| EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
| Nakamura et al. | Physiological functions of phospholipase Cδ1 and phospholipase Cδ3 | |
| PH12016500708A1 (en) | Recombinant glycoproteins and uses thereof | |
| BR112022026292A2 (pt) | Vetores de terapia gênica do vírus adeno-associado | |
| BR112019007028A2 (pt) | métodos e composições farmacêuticas para o tratamento do câncer renal | |
| BR112016005899A8 (pt) | composições compreendendo populações heterogêneas de proteínas de fator xa de coagulação recombinante humano, seus usos e método de purificação de uma proteína variante de fator xa. | |
| MX2019014697A (es) | Proteínas del receptor para productos finales de la glicación avanzada (rage) para el tratamiento de fibrosis y enfermedades mediadas por daño al adn. | |
| BR112017022715A2 (pt) | variante do polipeptídeo gal-1, ácido nucleico, composição farmacêutica, método para modular uma resposta imunológica e método para tratamento de um sujeito |